Beraprost sodium MR for the treatment of pulmonary arterial hypertension

Bibliography

• Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013;62:D42-50
   PubMed Web of Science ®Google Scholar
• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62:D34-41
   PubMed Web of Science ®Google Scholar
• Galie N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013;62:D60-72
   PubMed Web of Science ®Google Scholar
• Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008;51:1527-38
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Yaici A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010;36:549-55
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990;112:485-91
   PubMed Web of Science ®Google Scholar
• Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34
   PubMed Web of Science ®Google Scholar
• Vachiery JL, Hill N, Zwicke D, et al. Transitioning from i.V. Epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002;121:1561-5
   PubMed Web of Science ®Google Scholar
• Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006;129:1636-43
   PubMed Web of Science ®Google Scholar
• Okano Y, Yoshioka T, Shimouchi A, et al. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997;349:1365
   PubMed Web of Science ®Google Scholar
• Morita A, Kamoshita K, Ito T, et al. Beneficial effects of sodium salt of 17(r)-methyl-20-isopropylidenecarbacyclin on experimentally-induced ischemic hind limb lesions and blood viscosity. Arzneimittelforschung 1986;36:680-3
   Google Scholar
• Akiba T, Miyazaki M, Toda N. Vasodilator actions of trk-100, a new prostaglandin i2 analogue. Br J Pharmacol 1986;89:703-11
   PubMed Web of Science ®Google Scholar
• Umetsu T, Murata T, Nishio S. Studies on the antiplatelet effect of the stable epoprostenol analogue beraprost sodium and its mechanism of action in rats. Arzneimittelforschung 1989;39:68-73
   PubMed Web of Science ®Google Scholar
• Sim AK, McCraw AP, Cleland ME, et al. Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation. Arzneimittelforschung 1985;35:1816-18
   PubMed Web of Science ®Google Scholar
• Umetsu T, Murata T, Tanaka Y, et al. Antithrombotic effect of trk-100, a novel, stable pgi2 analogue. Jpn J Pharmacol 1987;43:81-90
   PubMedGoogle Scholar
• Nishio S, Matsuura H, Kanai N, et al. The in vitro and ex vivo antiplatelet effect of trk-100, a stable prostacyclin analog, in several species. Jpn J Pharmacol 1988;47:1-10
   PubMedGoogle Scholar
• Kajikawa N, Nogimori K, Murata T, et al. Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets. Arzneimittelforschung 1989;39:495-9
   Google Scholar
• Murata T, Sakaya S, Hoshino T, et al. General pharmacology of beraprost sodium. 1st communication: effect on the central nervous system. Arzneimittelforschung 1989;39:860-6
   Google Scholar
• Murata T, Murai T, Kanai T, et al. General pharmacology of beraprost sodium. 2nd communication: effect on the autonomic, cardiovascular and gastrointestinal systems, and other effects. Arzneimittelforschung 1989;39:867-76
   Google Scholar
• Christman BW. Lipid mediator dysregulation in primary pulmonary hypertension. Chest 1998;114:205S-7S
   PubMed Web of Science ®Google Scholar
• Moncada S, Gryglewski R, Bunting S, et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663-5
   PubMed Web of Science ®Google Scholar
• Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995;48:890-6
   PubMed Web of Science ®Google Scholar
• Gryglewski RJ. Interactions between endothelial mediators. Pharmacol Toxicol 1995;77:1-9
   Google Scholar
• Chow KB, Jones RL, Wise H. Protein kinase a-dependent coupling of mouse prostacyclin receptors to gi is cell-type dependent. Eur J Pharmacol 2003;474:7-13
   PubMed Web of Science ®Google Scholar
• Wise H. Multiple signalling options for prostacyclin. Acta Pharmacol Sin 2003;24:625-30
   PubMed Web of Science ®Google Scholar
• Abramovitz M, Adam M, Boie Y, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 2000;1483:285-93
   PubMed Web of Science ®Google Scholar
• Gupta RA, Tan J, Krause WF, et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA 2000;97:13275-80
   PubMed Web of Science ®Google Scholar
• Hatae T, Wada M, Yokoyama C, et al. Prostacyclin-dependent apoptosis mediated by ppar delta. J Biol Chem 2001;276:46260-7
   PubMed Web of Science ®Google Scholar
• Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 1997;94:4318-23
   PubMed Web of Science ®Google Scholar
• Lazennec G, Canaple L, Saugy D, et al. Activation of peroxisome proliferator-activated receptors (ppars) by their ligands and protein kinase a activators. Mol Endocrinol 2000;14:1962-75
   PubMed Web of Science ®Google Scholar
• Yang L, Yatomi Y, Satoh K, et al. Inhibitory effects of beraprost on platelet aggregation: comparative study utilizing two methods of aggregometry. Thromb Res 1999;94:25-32
   Google Scholar
• Demolis JL, Robert A, Mouren M, et al. Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers. J Cardiovasc Pharmacol 1993;22:711-16
   PubMed Web of Science ®Google Scholar
• Yuki H, Sato S, Arisaka Y, et al. Orally administered beraprost sodium inhibits pulmonary hypertension induced by monocrotaline in rats. Tohoku J Exp Med 1994;173:371-5
   PubMed Web of Science ®Google Scholar
• Miyata M, Ueno Y, Sekine H, et al. Protective effect of beraprost sodium, a stable prostacyclin analogue, in development of monocrotaline-induced pulmonary hypertension. J Cardiovasc Pharmacol 1996;27:20-6
   PubMedGoogle Scholar
• Ueno Y, Kawashima A, Koike H, et al. Effect of beraprost sodium, a stable prostacyclin analogue, on pulmonary thromboembolism in mice. Thromb Res 1995;77:193-8
   PubMed Web of Science ®Google Scholar
• Ueno Y, Koike H, Annoh S, et al. Effects of beraprost sodium, a prostacyclin analogue, on tail flick response in two models of diabetic-neuropathy in rats and its mechanism. Life Sci 1996;59:PL105-10
   Google Scholar
• Ishikawa M, Namiki A. The contractile mechanism of beraprost sodium, a stable prostacyclin analog, in the isolated canine femoral vein. Heart Vessels 1994;9:14-18
   Google Scholar
• Tamura M, Kurumatani H, Matsushita T. Comparative effects of beraprost, a stable analogue of prostacyclin, with pge(1), nitroglycerin and nifedipine on canine model of vasoconstrictive pulmonary hypertension. Prostaglandins Leukot Essent Fatty Acids 2001;64:197-202
   Google Scholar
• Ueno Y, Koike H, Annoh S, et al. Anti-inflammatory effects of beraprost sodium, a stable analogue of pgi2, and its mechanisms. Prostaglandins 1997;53:279-89
   PubMedGoogle Scholar
• Benyahia C, Boukais K, Gomez I, et al. A comparative study of pgi2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the dp-receptor. Prostaglandins Other Lipid Mediat 2013;107:48-55
   PubMed Web of Science ®Google Scholar
• Clapp LH, Finney P, Turcato S, et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic amp generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002;26:194-201
   PubMed Web of Science ®Google Scholar
• Kadowaki M, Mizuno S, Demura Y, et al. Effect of hypoxia and beraprost sodium on human pulmonary arterial smooth muscle cell proliferation: the role of p27kip1. Respir Res 2007;8:77
   Google Scholar
• Fukazawa T, Yajima K, Miyamoto Y. Evaluation of drug-drug interaction potential of beraprost sodium mediated by p450 in vitro. Yakugaku Zasshi 2008;128:1459-65
   Google Scholar
• Melian EB, Goa KL. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs 2002;62:107-33
   PubMed Web of Science ®Google Scholar
• Armstrong DWI, Negro-Vilar RC, Di Marino MED, et al. A phase 1, single-center, open-label, drug intercation study to evaluate the pharmacokinetics, safety, and tolerability of co-administered bps-mr and sildenail at steady-state in healthy subjects [abstract 5901]. Am J Respir Crit Care Med 2011;183
   Google Scholar
• Nagaya N, Shimizu Y, Satoh T, et al. Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension. Heart 2002;87:340-5
   PubMed Web of Science ®Google Scholar
• Vizza CD, Sciomer S, Morelli S, et al. Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart 2001;86:661-5
   PubMed Web of Science ®Google Scholar
• Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1188-92
   PubMed Web of Science ®Google Scholar
• Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-502
   PubMed Web of Science ®Google Scholar
• Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-25
   PubMed Web of Science ®Google Scholar
• Armstrong DJ, Benza R, Delcroix M, et al. Clinical pharmacology and safety of beraprost sodium modified release (bps-mr), an oral twice daily prostacyclin analogue – a phase II study [abstract 3360]. Am J Respir Crit Care Med 2010;181
   Google Scholar
• Ikeda D, Tsujino I, Sakaue S, et al. Pilot study of short-term effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertension. Circ J 2007;71:1829-31
   Google Scholar
• Oudiz R, Benza R, Delcroix M, et al. Long-term follow-up in pah patients dosed with modified release (bps-mr) tablets, an oral twice daily prostacyclin analogue [abstract 5905]. Am J Respir Crit Care Med 2011;183
   Google Scholar
• Jing ZC, Zhao QH, Jiang X, et al. Addition of beraprost to existing sildenail threapy in patients with pulmonary arterial hypertension: a randomized, open-label study (best study) [abstract 6066]. Am J Respir Crit Care Med 2013
   Google Scholar
• Kunieda T, Nakanishi N, Matsubara H, et al. Effects of long-acting beraprost sodium (trk-100stp) in japanese patients with pulmonary arterial hypertension. Int Heart J 2009;50:513-29
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Taha N, Bekjarova A, et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003;22:330-4
   PubMed Web of Science ®Google Scholar
• Deboeck G, Scoditti C, Huez S, et al. Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension. Eur Respir J 2012;40:1410-19
   PubMedGoogle Scholar
• Gabler NB, Franch B, Strom BL, et al. Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials. Circulation 2012;126:349-56
   PubMed Web of Science ®Google Scholar